secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001193125-25-157096
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis expands Tempus partnership to colorectal cancer MRD; term to 2029
----------------------------------------------------------------------------

- Tempus authorized to market NeXT Personal MRD test for colorectal cancer, fourth indication.
- Agreement term extended to November 25, 2029.
- Exclusivity period extended to December 31, 2028 for both parties on tumor-informed MRD in these indications.
- Standstill restrictions for Tempus modified to expire June 4, 2027 or end of exclusivity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/0001193125-25-157096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525157096/d26859d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-157096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer